GFM
AXSM icon

GF Fund Management’s Axsome Therapeutics AXSM Stock Holding History

GF Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Sell
1,085
-48
-4% -$10.4K ﹤0.01% 252
2026
Q1 		$192K Buy
1,133
+143
+14% +$24.7K ﹤0.01% 287
2025
Q4 		$181K Sell
990
-84
-8% -$11.7K ﹤0.01% 305
2025
Q3 		$130K Sell
1,074
-167
-13% -$18.8K ﹤0.01% 320
2025
Q2 		$130K Hold
1,241
– – ﹤0.01% 349
2025
Q1 		$145K Buy
1,241
+223
+22% +$25.4K ﹤0.01% 341
2024
Q4 		$86.1K Buy
+1,018
New +$93.6K ﹤0.01% 338

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GF Fund Management's AXSM Position: Q2 2026 in Review

GF Fund Management reduced its Axsome Therapeutics (AXSM) stake by 4.2% in Q2 2026, selling an estimated $10.4K and leaving 1,085 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #252.

GF Fund Management first reported a position in AXSM in Q4 2024 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • GF Fund Management held 1,085 shares of Axsome Therapeutics worth $266K as of Q2 2026.
  • GF Fund Management sold 48 Axsome Therapeutics shares in Q2 2026, an estimated $10.4K.
  • Axsome Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #252 holding.
  • GF Fund Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.